Imunon, Inc. (NASDAQ:IMNN), a pharmaceutical preparations company currently trading at $1.32 with a market capitalization of $29.2 million, has regained compliance with Nasdaq’s minimum bid ...

IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer of ...

Imunon, Inc. (NASDAQ:IMNN), a pharmaceutical preparations company currently trading at $1.32 with a market capitalization of $29.2 million, has regained compliance with Nasdaq’s minimum bid price ...

LAWRENCEVILLE, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy ...

Imunon, Inc. (NASDAQ:IMNN), a company operating in the biotechnology sector, is part of key market indexes such as the Top ...

LAWRENCEVILLE, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that Stacy ...

IMUNON presented translational data from its OVATION 2 Phase 2 study of IMNN-001, a DNA-based IL-12 immunotherapy for advanced ovarian cancer. The therapy showed dose-dependent increases in IL-12 ...